Arrowhead Pharmaceuticals Inc (ARWR)

6.89
1.19 14.73
NASDAQ : Health Care
Prev Close 8.08
Open 8.20
Day Low/High 6.68 / 8.22
52 Wk Low/High 3.07 / 9.36
Volume 3.08M
Avg Volume 535.80K
Exchange NASDAQ
Shares Outstanding 60.75M
Market Cap 470.82M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arrowhead Reports Fiscal 2016 Third Quarter Results

Arrowhead Reports Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016.

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million.

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, August 9, 2016, at 4:30 p.

Commit To Purchase Arrowhead Pharmaceuticals At $3, Earn 15% Using Options

Commit To Purchase Arrowhead Pharmaceuticals At $3, Earn 15% Using Options

Investors eyeing a purchase of Arrowhead Pharmaceuticals Inc shares, but cautious about paying the going market price of $5.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 45 cents.

Arrowhead Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Arrowhead Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV)...

Arrowhead Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Arrowhead Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.

Arrowhead Reports Fiscal 2016 Second Quarter Results

Arrowhead Reports Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016.

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown And Long Duration Of Effect After Subcutaneous Administration

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown And Long Duration Of Effect After Subcutaneous Administration

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the...

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.

Arrowhead Pharmaceuticals To Present At Upcoming May Conferences

Arrowhead Pharmaceuticals To Present At Upcoming May Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARC-521

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARC-521

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic...

First Week of December 16th Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week of December 16th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals Presents Preclinical Data On Renal Cell Carcinoma Program At AACR 2016

Arrowhead Pharmaceuticals Presents Preclinical Data On Renal Cell Carcinoma Program At AACR 2016

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-a for the treatment of renal cell carcinoma (RCC), at the American Association for...

Here’s Why Arrowhead Pharma (ARWR) Stock Closed Up Today

Here’s Why Arrowhead Pharma (ARWR) Stock Closed Up Today

Arrowhead Pharma (ARWR) stock continued to climb on Thursday after the release of ‘promising’ data about its lead product candidate for the treatment of the hepatitis B infection yesterday.

Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data

Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data

Arrowhead Pharma (ARWR) stock are rising following the release of encouraging data about the company's lead product candidate for the treatment of the hepatitis B virus infection.

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data At The International Liver Congress™ 2016

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data At The International Liver Congress™ 2016

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver...

Arrowhead Research Changes Name To Arrowhead Pharmaceuticals

Arrowhead Research Changes Name To Arrowhead Pharmaceuticals

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc.

Arrowhead To Present At Upcoming April Conferences

Arrowhead To Present At Upcoming April Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Presents Promising New Preclinical Data On ARC-F12 At AAAAI 2016

Arrowhead Presents Promising New Preclinical Data On ARC-F12 At AAAAI 2016

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented additional preclinical data suggesting that ARC-F12, an RNAi therapeutic that inhibits the...

Arrowhead To Present At Upcoming March Conferences

Arrowhead To Present At Upcoming March Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Research (ARWR) Weak On High Volume Today

Arrowhead Research (ARWR) Weak On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead To Present At Upcoming February Conferences

Arrowhead To Present At Upcoming February Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Reports Fiscal 2016 First Quarter Results

Arrowhead Reports Fiscal 2016 First Quarter Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2016 first quarter ended December 31, 2015.

Arrowhead Research (ARWR) Is Strong On High Volume Today

Arrowhead Research (ARWR) Is Strong On High Volume Today

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

Arrowhead To Webcast Fiscal 2016 First Quarter Results

Arrowhead To Webcast Fiscal 2016 First Quarter Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host a webcast and conference call on Tuesday, February 9, 2015, at 4:30 p.

Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation

Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to ARC-AAT for...

Arrowhead Begins Dosing The Phase 2b MONARCH Combination Study Of ARC-520 In Patients With Chronic Hepatitis B Infection

Arrowhead Begins Dosing The Phase 2b MONARCH Combination Study Of ARC-520 In Patients With Chronic Hepatitis B Infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, dosed the first patient in the Phase 2b MONARCH combination study of ARC-520, it's RNAi-based drug for the...